News & Events
-
November 1, 2017
FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics
Conrado, D.J., et al.; “FDA qualification of intracranial adjusted hippocampal volumetric magnetic resonance imaging (ICV-HV vMRI) as a prognostic biomarker for pre-dementia clinical trials for Alzheimer disease therapeutics.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, The Journal of Prevention of Alzheimer’s Disease 4(4): 345.... -
November 1, 2017
Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments
Arnerić, S.P., et al.; “Informed consent ensuring access to anonymized patient-level data and biospecimen is critical to accelerating innovative Alzheimer disease treatments.” 10th Clinical Trials on Alzheimer’s Disease (CTAD), Boston, MA, November 1-4, 2017, The Journal of Prevention of Alzheimer’s Disease 4(4): 387.... -
October 15, 2017
Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD)
Burton, J., et al.; “Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD).” The 8th American Conference on Pharmacometrics (ACoP8), Fort Lauderdale, FL, October 15-18, 2017.... -
October 15, 2017
Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers
Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers.” The 8th American Conference on Pharmacometrics (ACoP8), Fort Lauderdale, FL, October 15-18, 2017.... -
July 16, 2017
Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases
Kern, V.D., et al.; “Landscape analysis of biometric monitoring devices (BMDs) utilized in assessing cognition, sleep and mobility in Alzheimer’s disease and other age-related neurological diseases.” Alzheimer’s Association International Conference, London, UK, July 16-20, 2017, Alzheimer’s & Dementia 12(7): Suppl., 1322....